I
IX Biopharma Ltd
SGX:42C
IX Biopharma Ltd
SGX:42C
Price:
0.043 SGD
-10.42%
Market Closed
Updated:
May 8, 2024
IX Biopharma Ltd
Cash from Financing Activities
|
IX Biopharma Ltd
Cash from Financing Activities Peer Comparison
Comparables:
WVE
H02
H
1J5
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
I
|
IX Biopharma Ltd
SGX:42C
|
Cash from Financing Activities
S$736k
|
CAGR 3-Years
-58%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
WAVE Life Sciences Ltd
NASDAQ:WVE
|
Cash from Financing Activities
$132.5m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
Haw Par Corporation Ltd
SGX:H02
|
Cash from Financing Activities
-S$79.3m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-8%
|
|
H
|
Hyphens Pharma International Ltd
SGX:1J5
|
Cash from Financing Activities
-S$17.3m
|
CAGR 3-Years
-114%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is IX Biopharma Ltd's Cash from Financing Activities?
Cash from Financing Activities
736k
SGD
736k
SGD
Based on the financial report for Dec 31, 2023, IX Biopharma Ltd's Cash from Financing Activities amounts to 736k SGD.
What is IX Biopharma Ltd's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 3Y
-58%
-58%
Over the last year, the Cash from Financing Activities growth was -50%. The average annual Cash from Financing Activities growth rates for IX Biopharma Ltd have been -58% over the past three years .
You don't have any saved screeners yet
